Multiple Myeloma
US Focus Meeting 2026
📍 Boston, MA
🗓️ August 14 - 15, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Multiple Myeloma Focus Meeting 2026, to be held on August 14 - 15, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Multiple Myeloma research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Multiple Myeloma US Focus Meeting 2026:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
freya.symons@md-education.com
Agenda & Faculty
August 14, 2026 | Day 1
Session I: Diagnostic and Disease Monitoring Tools in Myeloma
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
09:00 AM
Role of Mass Spectrometry in Screening, Diagnosis, and Disease Monitoring
David L. Murray, MD
Mayo Clinic, Rochester, MN
09:15 AM
Can We Replace FISH Panel with Sequencing?
Mehmet K. Samur, MD
Dana-Farber Cancer Institute, Boston, MA
09:30 AM
MRD Monitoring in MM – Current Approaches
BD
Ben Derman, MD
The University of Chicago Medicine, IL
09:45 AM
Panel Discussion
09:45 AM
Panel Discussion
10:15 AM
Case Discussion: “Case of diagnosis with FISH and imaging and monitoring with MRD" followed by Q&A
Kevin Miller, MD
Massachusetts General Brigham Hospital, Boston, MA
10:30 AM
Coffee Break
Session II: Management of Precursor Conditions
Moderated by:
NM
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA
10:50 AM
Monoclonal Gammopathy – Diagnosis and Risk Adapted Approach to Monitoring
Natalie Callander, MD
UW Health, Madison, WI
11:05 AM
Smoldering Multiple Myeloma – Current Approaches to Management
Sagar Lonial, MD
Emory Winship Cancer Institute, Atlanta, GA
11:20 AM
Monoclonal Gammopathies – When Are They of Clinical Significance?
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
11:35 AM
Panel Discussion
12:20 PM
Industry Supported Independent Expert Discussion
01:05 PM
Lunch Break
Session III: Other Plasma Cell Disorders
Moderated by:
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
01:55 PM
Management of Light Chain Amyloidosis
Anita D’Souza, MD
Medical College of Wisconsin, Wauwatosa, WI
02:10 PM
Waldenström Macroglobulinemia
Prashant Kapoor, MD
Mayo Clinic, Rochester, MN
12:05 PM
Case Discussion: “Smoldering MM Patient” followed by Q&A
DPK
Dhauna Prasad Karam,
MBBS
Mayo Clinic, Rochester, MN
02:25 PM
Panel Discussion
02:55 PM
Case Discussion: “Waldenstrom’s case” followed by Q&A
Saurabh Zanwar, MBBS
Mayo Clinic, Rochester, MN
03:10 PM
Coffee Break
Session IV: Newly Diagnosed Multiple Myeloma
Moderated by:
Tom Martin, MD
UCSF Health, San Francisco, CA
03:30 PM
Integrating T-Cell Redirection Therapy into Newly Diagnosed MM Treatment
Surbhi Sidana, MD
Stanford Medicine, CA
03:45 PM
Does Transplant Have a Role in the Management of Myeloma – Upfront or Later?
Amrita Krishnan, MD
City of Hope, Duarte, CA
04:00 PM
Defining Frailty and Making Treatment Decisions
Ashley Rosko, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH
04:15 PM
Panel Discussion & Take-Home Points from Day 1
04:45 PM
Case Discussion: “newly diagnosed MM” followed by Q&A
BP
Benjamin Puliafito, MD
Massachusetts General Hospital, Boston, MA
05:00 PM
Adjourn
August 15, 2026 | Day 2
Session V: Individualizing Therapy in Myeloma – Role of Risk Stratification
Moderated by:
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
09:00 AM
How Do We Adapt Treatment to Baseline
Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY
09:15 AM
Integrating Response into Treatment Decisions
LC
Luciano Costa, MD
UAB Medicine, Birmingham, AL
09:30 AM
Management of Extramedullary Decisions
Wilson Gonsalves, MD
Mayo Clinic, Rochester, MN
09:45 AM
Panel Discussion & Take-Home Points from Day 1
10:15 AM
Case Discussion: “High risk patient with EMD” followed by Q&A
Emily Liang
Fred Hutchinson Cancer Center, Seattle, WA
10:30 AM
Coffee Break
Session VI: Management of Initial Relapse: Part 1
Moderated by:
NM
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA
10:50 AM
When Should We Start Treatment for Relapse?
Jonathan Kaufman, MD
Emory Winship Cancer Institute, Atlanta, GA
11:05 AM
Treatment at First Relapse – IMiD-PI-anti- CD38 Based Combinations Should Be First Choice
Binod Dhakal, MD
Medical College of Wisconsin, Wauwatosa, WI
11:20 AM
CAR-T Should Be the Treatment of Choice
Doris Hansen, MD
Moffitt Cancer Center, FL
13:35 AM
Panel Discussion
12:05 PM
Industry Supported Independent Expert Discussion
12:50 PM
Lunch Break
Session VII: Management of Initial Relapse: Part 2
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
01:40 PM
Bispecific Antibody Should Be the Treatment of Choice
Krina Patel, MD
Moffitt Cancer Center, FL
01:55 PM
ADC Should Be the Treatment Choice
Ajay Nooka, MD
Emory Winship Cancer Institute, Atlanta, GA
02:10 PM
Panel Discussion
02:40 PM
Case Discussion: “Case for Bispecific antibody” followed by Q&A
Narsis Attar, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
02:55 PM
Coffee Break
03:15 PM
Industry Supported Independent Expert Discussion
Session VIII: Management of Late Relapse
Moderated by:
Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY
04:00 PM
Novel Approaches to TCE Therapies - Bispecifics and Trispecifics
Andrew Yee, MD
Massachusetts General Hospital, Boston, MA
04:15 PM
Novel CAR-T Cell Approaches
Tom Martin, MD
UCSF Health, San Francisco, CA
04:30 PM
Targeted Therapies in MM - Moving Beyond Immunotherapy
Joshua Richter, MD
Icahn School of Medicine at Mount Sinai, New York, NY
04:45 PM
Panel Discussion & Take-Home Points from Day 2
05:15 PM
Case Discussion: “Case for lte relpse—either treated with Selinexor or novel CAR—in vivo or Arlocel” followed by Q&A
Nadine Abdallah, MD
Mayo Clinic, Rochester, MN
05:30 PM
Adjourn
Freya Symons
Project Manager
How long has Freya Symons been in the business?
Freya Symons has been with MD Education since 2025.
About Freya Symons
As a Project Manager at MD Education’s Wigan office, I support the smooth delivery of educational events through effective coordination, organisation, and communication. With a strong background in project-based work and a degree in Business Management and Marketing, I take pride in my attention to detail and ability to build positive working relationships. I am committed to supporting project teams and contributing to the delivery of high-quality projects. For me, seeing projects develop from initial ideas to successful delivery is what makes the role so rewarding.
